NCT06768827

Brief Summary

Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
47mo left

Started Nov 2025

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Nov 2025Mar 2030

First Submitted

Initial submission to the registry

January 6, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 10, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

November 13, 2025

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2030

Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

4.4 years

First QC Date

January 6, 2025

Last Update Submit

January 26, 2026

Conditions

Keywords

ObesityYouthInsulin ResistanceIntestinal Fermentation

Outcome Measures

Primary Outcomes (3)

  • CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)

    Changes in adipose tissue lipolysis occurring after colonic fermentation (stimulated by lactulose) will be compared between youth with obesity and insulin resistance (OIR) and with obesity and without insulin resistance (OIS). Lipolysis will be measured by using change in D5-glycerol concentration.

    6 hours

  • CHANGES IN GLUCONEOGENESIS

    Gluconeogenesis (GLC) will be measured using change in deuterium oxide concentration after colonic fermentation due to lactulose ingestion and compared between OIS and OIR.

    6 hours

  • CHANGES IN ADIPOSE TISSUE LIPOLYSIS (ATL)

    Changes in ATL due to colonic fermentation will be measured in two groups of OIR youth. One group will undergo physical activity for 12 weeks and another group will undergo a control intervention. Lipolysis will be measured by using change in D5-glycerol concentration.

    Baseline and 12 weeks

Secondary Outcomes (2)

  • CHANGES IN PEPTIDE YY (PYY) concentration

    Baseline and 12 weeks

  • CHANGES IN GHRELIN concentration

    Baseline and 12 weeks

Study Arms (2)

Remote physical exercise

EXPERIMENTAL
Other: Lactulose Oral Product

Control physical exercise

ACTIVE COMPARATOR
Other: Lactulose Oral Product

Interventions

Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.

Control physical exerciseRemote physical exercise

Eligibility Criteria

Age15 Years - 22 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 15 to 22 years
  • In puberty (girls and boys: Tanner stage III-V);
  • BMI \>85th

You may not qualify if:

  • Pregnancy;
  • endocrinopathies (e.g., Cushing syndrome);
  • substance abuse;
  • medications affecting insulin resistance such as metformin, GLP-1 analogues; -
  • high fibers intake (\> 30g/day) as assessed by a 3-day food record.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yale University

New Haven, Connecticut, 06520, United States

RECRUITING

MeSH Terms

Conditions

ObesityOverweightInsulin Resistance

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Study Officials

  • NICOLA SANTORO, MD, PhD

    Yale University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

NICOLA SANTORO, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 6, 2025

First Posted

January 10, 2025

Study Start

November 13, 2025

Primary Completion (Estimated)

March 31, 2030

Study Completion (Estimated)

March 31, 2030

Last Updated

January 28, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

Published IPD will be shared at the end of the study

Shared Documents
ANALYTIC CODE
Time Frame
a year after the completion of the study
Access Criteria
Published IPD will be made available as an appendix to the paper published using the data generated through FigShare or other websites.

Locations